KENDALL SELLING McGAW LABORATORIES FOR $210 MIL. and "other considerations" to an investor group headed by former Caremark exec James Sweeney, under a definitive agreement announced July 27. Headquartered in Irvine, California, McGaw manufactures generic pharmaceuticals, I.V. solutions, pumps and controllers. The business accounted for about $225 mil. of privately held Kendall's 1989 sales of $900 mil. Financing is being provided by Alex. Brown & Sons of Baltimore, Maryland and New York-based Donaldson, Lufkin & Jenrette Securities. Sweeney, who was a founder and former chairman of home I.V. treatment provider Caremark before its acquisition by Baxter, will serve as McGaw CEO. According to Donaldson, Lufkin & Jenrette, no decisions have been made as to the rest of the McGaw management team. The sale is part of an ongoing restructuring by Kendall, a former Colgate subsidiary that was taken private in 1988 via a$960 mil. management-led leveraged buyout. Kendall announced in June that McGaw and the Futuro home health care division would be offered for sale to "reduce substantially or retire the company's bank debt." The McGaw divestiture also allows Kendall to "focus resources on specialty institutional health care markets, including wound care, vascular compression, critical care and urology." Kendall's remaining businesses will be reorganized around the Kendall Healthcare Products division, headquartered in Mansfield, Massachusetts. The decision to sell McGaw coincides with an increase in competition in the I.V. products market, which is now dominated by multi-billion dollar corporations such as Abbott and Baxter. Characterizing McGaw as an "excellent business," Kendall CEO Richard Gilleland remarked that "we are confident the company can flourish under the ownership of Mr. Sweeney's group."
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Clinical trial sponsors in the rare disease space face “big safety demands” from regulators, which can be challenging for those with limited resources. A CRO founder makes the case for “embedding automation” into the clinical trial process to keep pace with regulatory requirements.
The developers of the ChAdOx1 NipahB vaccine will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.
The termination of the HHS Secretary’s Committee on Human Research Protections closed an important forum for discussing pediatrics and pregnancy in clinical trial design, a former SACHRP chair said.
